Lung Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 57 expanded access programs, clinical trials, and compassionate use pathways listed for Lung Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with lung cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 16 programs are currently active or recruiting, with the remaining 41 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, A2 Biotherapeutics Inc., H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), and others.
By recruiting status
Snapshot of where every Lung Cancer program currently sits in its lifecycle.
- Active / Recruiting16
- Inactive41
Top sponsors
Organisations running the most Lung Cancer programs in the directory.
- Memorial Sloan Kettering Cancer Center7 programs
- M.D. Anderson Cancer Center3 programs
- A2 Biotherapeutics Inc.2 programs
- H. Lee Moffitt Cancer Center and Research Institute2 programs
- National Cancer Institute (NCI)2 programs
- Tango Therapeutics, Inc.2 programs
- Apollomics Inc.1 program
- Arcus Biosciences, Inc.1 program
- AstraZeneca1 program
- Aura Biosciences1 program
Lung Cancer programs (57)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Zipalertinib vs. Placebo for Early Stage Non-Small Cell Lung Cancer with Uncommon EGFR Mutations After Tumor Removal — Taiho Oncology, Inc.
- Study on the Safety and Effectiveness of A2B395 CAR T-Cell Therapy for Solid Tumors with Specific Genetic Markers — A2 Biotherapeutics Inc.
- Study on the Safety and Effects of BMS-986507 Combinations in Adults with Advanced Solid Tumors — Bristol-Myers Squibb
- Study on PF-08634404 with Chemotherapy for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer — Pfizer
- Study on Afatinib with Chemotherapy and Radiation for EGFR-Mutant Non-Small Cell Lung Cancer — Massachusetts General Hospital
- Study on Axelopran for Advanced Cancer in Patients Using Opioids — HealthPartners Institute
- Study on Whether Durvalumab and Radiation Therapy Can Slow Down Non-Small Cell Lung Cancer — Memorial Sloan Kettering Cancer Center
- Study on Using Genetically Modified T Cells to Treat Malignant Pleural Disease — Memorial Sloan Kettering Cancer Center
- Study on MPDL3280A with Chemotherapy and Radiation for Lung Cancer — M.D. Anderson Cancer Center
- Study on Osimertinib and Abemaciclib for EGFR Mutant Non-Small Cell Lung Cancer After Resistance to Osimertinib — University of California, San Diego
- Study on Pembrolizumab and Vorinostat for Patients with Advanced Stage IV Non-Small Cell Lung Cancer — H. Lee Moffitt Cancer Center and Research Institute
- Study on the Safety and Tolerability of TNG456 Alone and with Abemaciclib in Patients with Solid Tumors with MTAP Loss — Tango Therapeutics, Inc.
- Study on the Effectiveness and Safety of Zimberelimab and Domvanalimab for Lung Cancer — Arcus Biosciences, Inc.
- Study on the Safety and Effectiveness of TNG462 Combination Therapy in Pancreatic and Lung Cancer Patients — Tango Therapeutics, Inc.
- Study on Suprachoroidal Administration for Patients with Eye Metastasis from Breast or Lung Cancer — Aura Biosciences
- Study on VMD-928 Alone and with Pembrolizumab for Treating Solid Tumors or Lymphoma with High TrkA Levels — VM Oncology, LLC
- Study on Pembrolizumab and Berahyaluronidase Alfa for Treating Newly Diagnosed Metastatic Non-Small Cell Lung Cancer — Merck Sharp & Dohme LLC
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Phase II Study of Sotorasib with Chemotherapy Before Surgery for Treatable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer with KRAS p.G12C Mutation — M.D. Anderson Cancer Center
- Study on the Safety and Effectiveness of NC410 and Pembrolizumab for Advanced Solid Tumors — NextCure, Inc.
- Study on Combining Cabozantinib and Atezolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Jun Zhang, MD, PhD
- Study on Different Radiation Doses for Patients Whose Cancer Progresses on Immunotherapy — Memorial Sloan Kettering Cancer Center
- Study on Stereotactic Radiosurgery for Lung Cancer That Has Spread to the Brain — Memorial Sloan Kettering Cancer Center
- Study Comparing Valemetostat Tosylate and Pembrolizumab with Pembrolizumab Alone for First-Line Treatment of NSCLC Without Specific Genetic Changes — Daiichi Sankyo
- Study on the Safety and Effectiveness of A2B694 CAR T-Cell Therapy for Solid Tumors with MSLN Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Adding Certolizumab to Chemotherapy and Nivolumab for Treating Lung Cancer That Can Be Surgically Removed — Memorial Sloan Kettering Cancer Center
- Study on Cisplatin-based Chemotherapy and Atezolizumab for Certain Stages of Resected Non-small Cell Lung Cancer (NSCLC) and Monitoring Circulating Tumor DNA — Nasser Hanna
- Study on Amivantamab with Tyrosine Kinase Inhibitors for Advanced Non-Small Cell Lung Cancer with ALK, ROS1, or RET Alterations — University of Colorado, Denver
- Study on Itacitinib and Osimertinib for Advanced Non-Small Cell Lung Cancer — Incyte Corporation
- Study on APL-101 for Treating Advanced Solid Tumors with Specific Genetic Changes — Apollomics Inc.
- Study on Alternating Treatment Plans for Advanced Lung or Head and Neck Cancer — Rutgers, The State University of New Jersey
- Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements — Joshua Palmer
- Study on Reduced Dose Chemotherapy for Lung Cancer Patients with Other Health Conditions — Fox Chase Cancer Center
- Study on Durvalumab and Radiation Therapy for Treating Extensive-Stage Small Cell Lung Cancer (DARES) — University of Chicago
- Early Access Program for Lazertinib in South Korea — Yuhan Corporation
- Expanded Access to NanoPac for Patients Not Eligible for Current Clinical Trials — NanOlogy, LLC
- Study on Using a Permanent Implantable Device to Treat Lung Cancer — CivaTech Oncology
- Study on M7824 and Topotecan or Temozolomide for Treating Relapsed Small Cell Lung Cancer — National Cancer Institute (NCI)
- Study on One-Time CT-Guided Radiation Treatment for Patients with Small Lung Tumors — Washington University School of Medicine
- Study on Restoring Lymphocytes Using NKTR-255 After Chemoradiotherapy in Solid Tumors (RESCUE) — M.D. Anderson Cancer Center
- Study on RMT with Durvalumab and Chemotherapy for Untreated Adenocarcinoma Non-Small Cell Lung Cancer — Masonic Cancer Center, University of Minnesota
- Study on the Safety and Effectiveness of Radiation Therapy Combined with Durvalumab for Treating Residual Lung Cancer — University of Nebraska
- Study on the Safety and Effectiveness of OBX-115 for Advanced Solid Tumors — Obsidian Therapeutics, Inc.
- Study on Stereotactic Ablative Radiotherapy (SABR) for Treating Patients with Metastatic Cancer, ID-COMET Trial — Roswell Park Cancer Institute
- Study on Stereotactic Brain Radiation with or without AGuIX Gadolinium-Based Nanoparticles for Brain Metastases — Dana-Farber Cancer Institute
- Study on QBS72S for Treating Brain Metastases in Advanced Breast Cancer — Melanie Hayden Gephart
- Study on EOS-448 with Standard and Experimental Treatments for Advanced Solid Tumors — iTeos Belgium SA
- Study on Pembrolizumab and Valemetostat for Treating Certain Head and Neck Cancers — National Cancer Institute (NCI)
- Study on JDQ443 for Patients with Advanced Solid Tumors with KRAS G12C Mutation — Novartis Pharmaceuticals
- Study on New Treatment Combinations for Lung Cancer Patients — Gilead Sciences
- Study on Trilaciclib and Lurbinectedin for Small Cell Lung Cancer — UNC Lineberger Comprehensive Cancer Center
- Study to Investigate Luveltamab Tazevibulin in Adults with Advanced or Metastatic Non-small Cell Lung Cancer — Sutro Biopharma, Inc.
- Study on Targeting ODC as an Immunotherapy for Advanced Non-Small Cell Lung Cancer with STK11 Mutation — H. Lee Moffitt Cancer Center and Research Institute
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Phase II Study of Osimertinib Treatment Before and After Chemoradiotherapy in Unresectable Stage III EGFRm Non-Small Cell Lung Cancer (NSCLC) — AstraZeneca
- Treating Early-stage Non-Small Cell Lung Cancer with Durvalumab and Radiation Therapy — Memorial Sloan Kettering Cancer Center
- Study on Ado-Trastuzumab Emtansine for Patients with HER2 Amplified or Mutant Cancers — Memorial Sloan Kettering Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Lung Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.